Gilead Sciences consensus picture, shares steady on NASDAQ

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 10:58.

Gilead Sciences (US3755581036) starts Tuesday with its shares traded on NASDAQ under the ticker GILD and a wide analyst coverage on the biotech sector. The consensus framework around the stock centers on antiviral revenues, oncology growth ambitions and ongoing R&D spending.

What analysts focus on

Analyst coverage on Gilead Sciences typically tracks trends in HIV and hepatitis C therapies, where the company historically generated significant cash flows and maintained leading market positions alongside peers such as Pfizer and Merck. Rating distributions across major houses often cluster around Hold and Buy, reflecting balanced views on legacy franchises and newer oncology assets.

Consensus commentary tends to highlight the importance of regulatory decisions for new indications, pricing dynamics in key US and European markets, and competition from generics and rival branded therapies. Analysts regularly update revenue and earnings models following quarterly results, adjusting assumptions for patient volumes, drug mix and currency effects.

How the consensus shapes the stock

On NASDAQ, Gilead Sciences shares trade as part of the broader US biotech cohort, where sentiment is influenced by clinical trial outcomes, FDA and EMA approvals and broader risk appetite for healthcare equities. Consensus estimates feed into valuation metrics such as forward price-to-earnings and enterprise value-to-sales ratios, which investors monitor against peers in large-cap biotech.

For institutional and retail investors, analyst reports provide structured scenarios for Gilead's earnings trajectory, often including base, bull and bear cases around pipeline success rates and lifecycle management of existing therapies. These scenarios help frame expectations for potential dividend capacity, buybacks and reinvestment into research programs.

How Gilead Sciences makes money

Gilead Sciences generates revenue primarily through branded antiviral medicines for HIV and liver diseases, including widely used combination therapies in tablet form. In addition, the company has built an oncology portfolio with targeted therapies and cell-based treatments, expanding addressable markets beyond infectious diseases.

Where the shares trade today

The Gilead Sciences shares (US3755581036) trade on NASDAQ under the ticker GILD in US dollars; as of 2026-06-30, 10:58, the latest price information on the US listing serves as the reference for investors.

This article is for informational purposes only and does not constitute investment advice, tax advice or a recommendation to buy or sell securities. All data and facts are based on publicly available information believed to be reliable at the time of review, but may change over time.